Poseida Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

poseida.com

Stage

IPO | IPO

Total Raised

$323.66M

Date of IPO

7/10/2020

Market Cap

0.13B

Stock Price

2.05

About Poseida Therapeutics

Poseida Therapeutics is a clinical-stage biotechnology company translating gene engineering technologies into lifesaving treatments for patients with high unmet medical need. The company is developing a wholly-owned pipeline of autologous and allogeneic CAR-T product candidates, initially focused on the treatment of hematological malignancies and solid tumors, as well as gene therapies for orphan genetic diseases.

Poseida Therapeutics Headquarter Location

9390 Towne Centre Drive Suite 200

San Diego, California, 92121,

United States

(858)-779-3100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Poseida Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Poseida Therapeutics is included in 4 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Poseida Therapeutics Patents

Poseida Therapeutics has filed 34 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/28/2017

1/4/2022

Molecular biology, Transcription factors, Biotechnology, Restriction enzymes, Small nuclear RNA

Grant

Application Date

4/28/2017

Grant Date

1/4/2022

Title

Related Topics

Molecular biology, Transcription factors, Biotechnology, Restriction enzymes, Small nuclear RNA

Status

Grant

Latest Poseida Therapeutics News

08:00 EDT Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders

Jun 2, 2022

News provided by Share this article Share this article SAN DIEGO, June 2, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX ), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that its virtual Annual Meeting of Stockholders (the "Annual Meeting") will be held on Thursday, June 16, 2022 at 1:00 p.m. PT. The Annual Meeting will be held through a live webcast. Stockholders of record at the close of business on April 20, 2022, are entitled to vote in the Annual Meeting. As provided in the Company's proxy materials, an online portal is available to stockholders at www.proxydocs.com/PSTX where stockholders can view and download the Company's proxy materials and 2021 Annual Report and vote their shares in advance of the Annual Meeting. Stockholders may also submit questions and vote their shares prior to the Annual Meeting by following the instructions available on the Annual Meeting website. To be admitted to the Annual Meeting, stockholders must register by 8:00 p.m. PT on June 14, 2022 at www.proxydocs.com/PSTX . To register, stockholders must enter the control number found on the proxy card in the materials sent to stockholders. After registration is complete, further instructions including a unique link to access the virtual Annual Meeting will be emailed. Poseida encourages stockholders to access the Annual Meeting prior to the start time in order to allow ample time for check-in procedures. Below are additional details on how stockholders can participate in the virtual Annual Meeting: Access the Annual Meeting website beginning at 12:45 p.m. PT on June 16, 2022. Vote during the Annual Meeting by following the instructions available on the Annual Meeting website. Submit a question in advance of the meeting by visiting the Annual Meeting website and entering the stockholder's control number. Whether or not a stockholder plans to attend the virtual-only Annual Meeting, Poseida Therapeutics urges each stockholder to vote and submit their proxy in advance of the meeting by one of the methods described in the proxy materials. About Poseida Therapeutics, Inc. Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit  www.poseida.com and connect with us on  Twitter  and  LinkedIn . SOURCE Poseida Therapeutics, Inc.

Poseida Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Poseida Therapeutics Rank

  • Where is Poseida Therapeutics's headquarters?

    Poseida Therapeutics's headquarters is located at 9390 Towne Centre Drive, San Diego.

  • What is Poseida Therapeutics's latest funding round?

    Poseida Therapeutics's latest funding round is IPO.

  • How much did Poseida Therapeutics raise?

    Poseida Therapeutics raised a total of $323.66M.

  • Who are the investors of Poseida Therapeutics?

    Investors of Poseida Therapeutics include Rapha Capital Management, Fidelity Investments, Schonfeld Strategic Advisors, Adage Capital Management, Malin Corporation and 11 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.